PYC Therapeutics (ASX:PYC) said the safety review committee governing its multiple dose studies in patients with retinitis pigmentosa type 11 approved escalation in dosing to the final patient group in the combined phase 1/2 studies of drug candidate VP-001, according to a Tuesday filing with the Australian bourse.
Retinitis pigmentosa type 11 is a blinding eye disease affecting one in every 100,000 people, the filing said.
Patients in the 75-microgram group of the multiple ascending dose (MAD) study can be enrolled in the trial and receive their first dose of VP-001 before the end of the month, according to the filing.
The final patient group data from the MAD study, expected to be available in the first quarter of 2025, will aid in collaborating with the US Food and Drug Administration on the design of the registrational study to support a new drug application for VP-001.
PYC Therapeutics shares fell nearly 3% in morning trade Tuesday.
Price (AUD): $0.19, Change: $-0.01, Percent Change: -2.63%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.